25 August 2010 - Antitope Ltd. of Cambridge UK (“Antitope”) today announced a research collaboration with Ablynx NV of Ghent, Belgium ("Ablynx") whereby Antitope will apply its proprietary EpiScreenTM technology to profile a series of Nanobodies® developed by Ablynx for possible T cell epitopes.
“We are delighted to be working with Ablynx whose Nanobody-based therapeutic research programmes represent exciting new opportunities in a range of major disease areas” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "We look forward to applying the EpiScreenTM technology to enable Ablynx to select Nanobodies with the lowest potential for immunogenicity."
Dr Hilde Revets, Senior Research Fellow of Ablynx added: “We are looking forward to our collaboration with Antitope. This study will help to further characterise our Nanobody platform.”
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
For further information on Antitope visit;
http://www.antitope.co.uk or contact:
Dr. Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
Nanobody is a registered trademark of Ablynx NV